GN
Gopal Naik Vankadothu
About Gopal Naik Vankadothu
Data last updated:
Gopal Naik Vankadothu is a Director at Apicem Pharmaceuticals Private Limited (since 2024), Director at Nirlepa Pharmaceuticals Private Limited (since 2025) and Director at Newloris Pharmaceuticals Private Limited (since 2024). The companies operate in Chemicals and Pharma. The largest current company by reported revenue is Apicem Pharmaceuticals Private Limited at ₹29 Lakh (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 31 May 2024 | 2020 | ₹29 Lakh (FY 2024) | Active | |
| Director | 22 Apr 2025 | 2025 | Active | ||
| Director | 30 Dec 2024 | 2024 | Active |
Board colleagues of Gopal Naik Vankadothu
| Name | DIN | Company | Designation |
|---|---|---|---|
| Sravanthi Vankudoth | 08943804 | Apicem Pharmaceuticals Private Limited , Newloris Pharmaceuticals Private Limited | Director |
| Sandeep Kumar Srivandla | 09681581 | Nirlepa Pharmaceuticals Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Gopal Naik Vankadothu
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gopal Naik Vankadothu
Gopal Naik Vankadothu currently holds 3 directorships: Apicem Pharmaceuticals Private Limited (Director, since 31 May 2024, revenue ₹29 Lakh (FY 2024)); Nirlepa Pharmaceuticals Private Limited (Director, since 22 Apr 2025); Newloris Pharmaceuticals Private Limited (Director, since 30 Dec 2024).
Gopal Naik Vankadothu was first appointed on 31 May 2024 as Director at Apicem Pharmaceuticals Private Limited. The most recent appointment on record is 22 Apr 2025 at Nirlepa Pharmaceuticals Private Limited.
The current boards of Gopal Naik Vankadothu's companies include Sravanthi Vankudoth (Apicem Pharmaceuticals Private Limited), Sandeep Kumar Srivandla (Nirlepa Pharmaceuticals Private Limited).